Novo Nordisk A/S

NYSE:NVO

Drug Manufacturers - General

Healthcare
$39.43 -1.09%

-$0.48 today

Market cap
$173.82B
Beta
0.35
P/E (TTM)
10.2
EPS (TTM)
$27.45
Dividend yield
4.18%
52W Low $35.12High $74.38

Volume 16.12M

Average 16.05M

NVO EBITDA Margin

EBITDA as a percentage of revenue.

Novo Nordisk A/SNYSE: NVO

EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026

EBITDA Margin narrows to 49.3%

EBITDA Margin was 49.3% in Q2 FY2026, down 7.4 pp from a year earlier. On a trailing-twelve-month basis it was 54.9%, down 0.5 pp year over year. Over 3 fiscal years it widened by 7.3 pp.

Context

  • EBITDA Margin widened in 2 of the last 3 fiscal years.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 16 analysts of 50.8% for the fiscal year ending Dec 2026, up from 50.7% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
49.3%-22.2 pp QoQ
Last fiscal yearDec 2025
50.7%-0.2 pp YoY
LTMJun 2026
54.9%-0.5 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-7.4 pp+13.1 pp+20.5 pp
1 year-0.2 pp+0.0 pp+0.3 pp
3 years+7.3 pp+1.3 pp-6.0 pp
5 years+4.6 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
50.7%
Year-over-year change
-0.2pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How NVO compares with its peers on the latest reported figures

  • NVO's LTM Jun 2026 EBITDA Margin of 54.9% is the highest of the 10 companies compared; the peer median is 31.0%.
  • Its year-over-year change of -0.5 pp is the 6th highest of 10, against a peer median of +0.6 pp.
  • Over three fiscal years its change of +7.3 pp compares with a peer median of +2.5 pp.
NVO Competitors Peer median
EBITDA Margin for NVO and competitors
Company Period LTM level YoY 3-year change
NVONovo Nordisk A/SLTM Jun 202654.9% -0.5 pp+7.3 pp
LLYEli Lilly and CompanyLTM Jun 202654.4% +14.4 pp+18.3 pp
AMGNAmgen Inc.LTM Jun 202646.2% +0.7 pp-0.2 pp
ABBVAbbVie Inc.LTM Sep 202636.6% +15.1 pp-12.8 pp
AZNAstraZeneca PLCLTM Sep 202634.4% +3.4 pp+13.3 pp
JNJJohnson & JohnsonLTM Sep 202631.0% -11.9 pp+10.3 pp
SNYSanofiLTM Jun 202630.2% +0.6 pp-6.6 pp
GSKGSK plcLTM Jun 202626.5% -0.7 pp+2.5 pp
PFEPfizer Inc.LTM Jun 202621.2% -10.4 pp-13.7 pp
MRKMerck & Co., Inc.LTM Jun 202621.0% -18.3 pp+7.6 pp
Peer median (excluding NVO) 31.0%+0.6 pp+2.5 pp

Competitors are the stored peer set for NVO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

DKK
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue140.8B176.95B232.26B290.4B309.06B
Cost of Revenue23.66B28.45B35.77B44.52B58.79B
Gross Profit117.14B148.51B196.5B245.88B250.28B
Gross Margin83.2%83.9%84.6%84.7%81.0%
Research & Development17.77B24.05B32.44B48.06B52.04B
Selling, General & Admin41.06B50.68B61.6B67.38B70.28B
Operating Expenses58.5B73.7B93.92B117.54B122.62B
Depreciation & Amortization6.03B7.36B9.41B19.11B21.98B
EBITDA65.39B76.8B114.63B147.94B156.73B
EBITDA Margin46.4%43.4%49.4%50.9%50.7%
Operating Income58.64B74.81B102.57B128.34B127.66B
Operating Margin41.7%42.3%44.2%44.2%41.3%
Interest Income231M239M1.07B1.84B1.27B
Interest Expense289M378M542M1.64B4.21B
Other Income / Expenses436M(5.75B)2.1B(1.15B)2.88B
Income Before Tax59.08B69.06B104.67B127.19B130.54B
Pre-Tax Margin42.0%39.0%45.1%43.8%42.2%
Income Tax Expense11.32B13.54B20.99B26.2B28.11B
Net Income47.76B55.53B83.68B100.99B102.43B
Net Margin33.9%31.4%36.0%34.8%33.1%
EPS (Basic)10.4012.2618.6722.6723.06
EPS (Diluted)10.3712.2218.6222.6323.03
Weighted Avg Shares4.59B4.53B4.48B4.45B4.45B
Weighted Avg Shares (Diluted)4.61B4.54B4.49B4.46B4.45B

Novo Nordisk A/S

NYSE:NVO

Intrinsic Alpha fair value

Locked

Current Price

$39.43

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.